December 6, 2022Open Access

Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer

Key Points

Key points are not available for this paper at this time.

Abstract

Pharmacologic inhibition of KRASG12D in pancreatic cancer models with an intact immune system stimulates specific, potent, and durable tumor regressions. In the absence of overt toxicity, these results suggest that this and similar inhibitors should be tested as potential, high-impact novel therapies for patients with PDAC. See related commentary by Redding and Grabocka, p. 260. This article is highlighted in the In This Issue feature, p. 247.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Samantha B. Kemp

Noah Cheng

Nune Markosyan

Journals

Cancer Discovery

Actions

Institutions

University of Pennsylvania

University of California, Los Angeles

UPMC Hillman Cancer Center

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study

Also consider